EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study

Krittiya Korphaisarn, Kosin Wirasorn, Suebpong Tanasanvimon, Kijjakom Thanasombunsukh, Kunlatida Maneenil, Jirawat Thanestada, Nattaya Teeyapun, Jarin Chindaprasirt, Chirawadee Sathitruangsak, Teerada Siripoon, Phannin Tiraswasdichai, Chanchai Charonpongsuntorn und 5 weitere

Oncology Research · 2026 · 1-10

DOI: 10.32604/or.2026.083206 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research, 2026. Verfasst von Krittiya Korphaisarn und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Hepatocellular carcinomaSTRIDE regimendurvalumabimmunotherapyreal-world outcomestremelimumab

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizeddurvalumabtremelimumab

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University, Bangkok, Thailand.
  • Department of Medicine, Lampang Hospital, Lampang, Thailand.
  • Oncology Unit, Rajavithi Hospital, Faculty of Medicine of Rangsit University, Bangkok, Thailand.
  • Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand.

Zitieren

APA

Korphaisarn, K., Wirasorn, K., Tanasanvimon, S., Thanasombunsukh, K., Maneenil, K., Thanestada, J., Teeyapun, N., Chindaprasirt, J., Sathitruangsak, C., Siripoon, T., Tiraswasdichai, P., Charonpongsuntorn, C., Wanchaijiraboon, P., Laosuangkoon, W., Sunpaweravong, P., Sirachainan, E., & Akewanlop, C. (2026). Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study. Oncology Research, 0(0), 1-10. https://doi.org/10.32604/or.2026.083206

Vancouver

Korphaisarn K, Wirasorn K, Tanasanvimon S, Thanasombunsukh K, Maneenil K, Thanestada J, et al. Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study. Oncology Research. 2026;0(0):1-10. doi:10.32604/or.2026.083206

BibTeX
@article{Korphaisarn2026,
  author = {Korphaisarn, Krittiya and Wirasorn, Kosin and Tanasanvimon, Suebpong and Thanasombunsukh, Kijjakom and Maneenil, Kunlatida and Thanestada, Jirawat and Teeyapun, Nattaya and Chindaprasirt, Jarin and Sathitruangsak, Chirawadee and Siripoon, Teerada and Tiraswasdichai, Phannin and Charonpongsuntorn, Chanchai and Wanchaijiraboon, Passakorn and Laosuangkoon, Wannisa and Sunpaweravong, Patrapim and Sirachainan, Ekapop and Akewanlop, Charuwan},
  title = {Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study},
  journal = {Oncology Research},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {1--10},
  doi = {10.32604/or.2026.083206}
}
Kostenlos starten →